MED
MEDIFAST INC
$11.27
-5.61%
$125.3M
No data for this timeframe.
Vol
Market Cap$125.3M
Cap SizeMicro Cap
Inst. Holders48 funds
Inst. Value$69.1M
Inst. Activity4 buys / 4 sells
Insider Activity3B / 0S
Insider Net $$241.7K
SEC Reports3
Press Releases4
Exchange NYSE·Sector Miscellaneous Food Preparations & Kindred Products·Inc. DE·CIK 0000910329·Prev Close $11.94
Recent Activity
Jun 11, 2026
other
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
OPTAVIA's clinical program reduces visceral fat 14% and retains 98% lean mass, directly addressing t
Jun 1, 2026
SEC
Medifast's Chief Legal Officer & Corporate Secretary Jason Groves resigned effective May 29, 2026, with a standard separ
8-K — Impact 2/10
May 26, 2026
SEC
Medifast filed an 8-K reporting stockholder approval of an amended share incentive plan and the formal appointment of Ni
8-K — Impact 3/10
May 26, 2026
Insider
Xian Ming was granted 11,680 shares
Director
May 26, 2026
Insider
Geary Elizabeth A. was granted 11,680 shares
Director
May 26, 2026
Insider
SCHLACKMAN SCOTT was granted 11,680 shares
Director
May 4, 2026
SEC
Medifast reported Q1 2026 revenue of $76.0M, down 34.3% YoY, and a net loss of $0.19 per share, widening from a $0.07 lo
8-K — Impact 7/10
Inst.
Lido Advisors, LLC — TRIM
183,035 shares ($1.9M)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.00 (Feb 2026)
Current $11.27
Low $12.00
Median $12.00
High $12.00
1 analysts
$12.00
$12.00
Analyst Ratings
0Strong Buy
0Buy
4Hold
4Sell
1Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 19, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.65 ▼ -51.2% | $-0.65 — $-0.65 | -395% YoY | 1 |
| Next Q | $-0.62 ▼ -63.2% | $-0.62 — $-0.62 | -195% YoY | 1 |
| Current FY | $-1.85 ▲ +6.6% | $-1.85 — $-1.85 | -9% YoY | 1 |
| Next FY | $-0.60 ▲ +78.3% | $-0.60 — $-0.60 | 68% YoY | 1 |
Latest Reports
NEUTRAL
8-K
2/10
Medifast's Chief Legal Officer & Corporate Secretary Jason Groves resigned effective May 29, 2026, with a standard separ
Jun 1, 2026
NEUTRAL
8-K
3/10
Medifast filed an 8-K reporting stockholder approval of an amended share incentive plan and the formal appointment of Ni
May 26, 2026
NEUTRAL
Press
2/10
Medifast (MED) issued a press release highlighting OPTAVIA's clinical evidence differentiating its coach-guided metaboli
May 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $9.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $7.9M | — |
| CITADEL ADVISORS LLC | $7.3M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $6.4M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.5M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 26, 2026 | Xian Ming | A | $0.00 |
| May 26, 2026 | Geary Elizabeth | A | $0.00 |
| May 26, 2026 | SCHLACKMAN SCOTT | A | $0.00 |
| May 26, 2026 | Thomas Andrea | A | $0.00 |
| May 26, 2026 | Kiai Parsa | A | $0.00 |
48 institutional holders with $69.1M total value (6,807,039 shares) as of 2026-Q1. Top holders: BlackRock,, RENAISSANCE, CITADEL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 944,453 | $9.6M | 13.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 773,710 | $7.9M | 11.4% | — |
| 3 | CITADEL ADVISORS LLC | 712,800 | $7.3M | 10.5% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 631,539 | $6.4M | 9.3% | ADD +30.5% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 444,467 | $4.5M | 6.6% | — |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 435,400 | $4.4M | 6.4% | — |
| 7 | DIMENSIONAL FUND ADVISORS LP | 361,762 | $3.7M | 5.3% | ADD +35.4% |
| 8 | TWO SIGMA INVESTMENTS, LP | 338,158 | $3.4M | 5.0% | TRIM -64.9% |
| 9 | MORGAN STANLEY | 325,312 | $3.3M | 4.8% | TRIM -43.1% |
| 10 | STATE STREET CORP | 222,638 | $2.3M | 3.3% | — |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 202,829 | $2.1M | 3.0% | — |
| 12 | Lido Advisors, LLC | 183,035 | $1.9M | 2.7% | TRIM -44.7% |
| 13 | Trexquant Investment LP | 180,081 | $1.8M | 2.7% | ADD +41.8% |
| 14 | D. E. Shaw & Co., Inc. | 160,564 | $1.6M | 2.4% | — |
| 15 | GOLDMAN SACHS GROUP INC | 153,171 | $1.6M | 2.3% | — |
| 16 | PEAK6 LLC | 90,100 | $918.1K | 1.3% | — |
| 17 | BANK OF AMERICA CORP /DE/ | 88,777 | $904.6K | 1.3% | NEAR_EXIT -78.5% |
| 18 | D. E. Shaw & Co., Inc. | 72,700 | $740.8K | 1.1% | — |
| 19 | VANGUARD FIDUCIARY TRUST CO | 67,040 | $683.1K | 1.0% | — |
| 20 | FEDERATED HERMES, INC. | 63,921 | $651.4K | 0.9% | TRIM -56.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Lido Advisors, LLC | TRIM | 330,703 | 183,035 | -44.7% | $1.9M | 2026-Q1 |
| Trexquant Investment LP | ADD | 126,959 | 180,081 | +41.8% | $1.8M | 2026-Q1 |
| Centiva Capital, LP | ADD | 13,885 | 22,022 | +58.6% | $224.4K | 2026-Q1 |
| CWM, LLC | ADD | 7,091 | 9,034 | +27.4% | $92.1K | 2026-Q1 |
| FMR LLC | NEAR_EXIT | 38,401 | 2,578 | -93.3% | $26.3K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 1,165 | 594 | -49.0% | $6.1K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 42 | 226 | +438.1% | $2.3K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 103 | 73 | -29.1% | $744.00 | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 595,211 | 776,829 | +30.5% | $8.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 588,539 | 334,858 | -43.1% | $3.6M | 2025-Q4 |
| Trexquant Investment LP | ADD | 67,520 | 126,959 | +88.0% | $1.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 452,543 | 97,473 | -78.5% | $1.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 228,799 | 80,340 | -64.9% | $858.0K | 2025-Q4 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 63,414 | 44,050 | -30.5% | $470.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 10,348 | 14,169 | +36.9% | $151.3K | 2025-Q4 |
| AMERIPRISE FINANCIAL INC | NEAR_EXIT | 57,836 | 13,019 | -77.5% | $139.0K | 2025-Q4 |
| Russell Investments Group, Ltd. | TRIM | 9,663 | 2,994 | -69.0% | $32.0K | 2025-Q4 |
| Allworth Financial LP | TRIM | 93 | 42 | -54.8% | $449.00 | 2025-Q4 |
| CWM, LLC | TRIM | 15,849 | 7,091 | -55.3% | $76.00 | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 421,169 | 595,211 | +41.3% | $8.1M | 2025-Q3 |
| MORGAN STANLEY | ADD | 457,786 | 588,539 | +28.6% | $8.0M | 2025-Q3 |
| Trexquant Investment LP | TRIM | 98,606 | 67,520 | -31.5% | $923.0K | 2025-Q3 |
| Allianz Asset Management GmbH | DOUBLED | 21,842 | 52,859 | +142.0% | $722.6K | 2025-Q3 |
| UBS Group AG | TRIM | 110,829 | 33,757 | -69.5% | $461.5K | 2025-Q3 |
| Russell Investments Group, Ltd. | TRIM | 18,358 | 9,663 | -47.4% | $132.1K | 2025-Q3 |
9 unique insiders with 21 transactions. Net insider value: $241.7K ($241.7K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 26, 2026 | Xian Ming | Director | AWARD | 11,680 | — | — |
| May 26, 2026 | Geary Elizabeth A. | Director | AWARD | 11,680 | — | — |
| May 26, 2026 | SCHLACKMAN SCOTT | Director | AWARD | 11,680 | — | — |
| May 26, 2026 | Thomas Andrea B | Director | AWARD | 11,680 | — | — |
| May 26, 2026 | Kiai Parsa | Director | AWARD | 11,680 | — | — |
| May 26, 2026 | Rose Jeffrey Matthew | Director | AWARD | 11,680 | — | — |
| May 11, 2026 | SCHLACKMAN SCOTT | Director | BUY | 2,500 | $12.53 | $31.3K |
| May 8, 2026 | SCHLACKMAN SCOTT | Director | BUY | 2,500 | $12.65 | $31.6K |
| Mar 25, 2026 | Chard Daniel R | Chairman & CEO | TAX W/H | 20,095 | $9.59 | $192.7K |
| Mar 25, 2026 | Chard Daniel R | Chairman & CEO | AWARD | 36,968 | — | — |
| Mar 25, 2026 | Maloney James P. | Chief Financial Officer | TAX W/H | 3,224 | $9.59 | $30.9K |
| Mar 25, 2026 | Maloney James P. | Chief Financial Officer | AWARD | 34,344 | — | — |
| Mar 25, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | TAX W/H | 862 | $9.59 | $8.3K |
| Mar 25, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | AWARD | 10,830 | — | — |
| Mar 20, 2026 | Chard Daniel R | Chairman & CEO | BUY | 17,678 | $10.11 | $178.7K |
| Mar 17, 2026 | Chard Daniel R | Chairman & CEO | TAX W/H | 2,638 | $10.05 | $26.5K |
| Mar 17, 2026 | Maloney James P. | Chief Financial Officer | TAX W/H | 482 | $10.05 | $4.8K |
| Mar 17, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | TAX W/H | 70 | $10.05 | $703.50 |
| Mar 13, 2026 | Chard Daniel R | Chairman & CEO | TAX W/H | 7,075 | $9.62 | $68.1K |
| Mar 13, 2026 | Maloney James P. | Chief Financial Officer | TAX W/H | 918 | $9.62 | $8.8K |
| Mar 13, 2026 | MacKenzie Jonathan Barrett | VP, Finance & CAO | TAX W/H | 198 | $9.62 | $1.9K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
2/10
Medifast's Chief Legal Officer & Corporate Secretary Jason Groves resigned effective May 29, 2026, w
Jun 1, 2026
NEUTRAL
8-K
3/10
Medifast filed an 8-K reporting stockholder approval of an amended share incentive plan and the form
May 26, 2026
BEARISH
8-K
7/10
Medifast reported Q1 2026 revenue of $76.0M, down 34.3% YoY, and a net loss of $0.19 per share, wide
May 4, 2026
NEUTRAL
2/10
Medifast (MED) issued a press release highlighting OPTAVIA's clinical evidence differentiating its c
May 21, 2026
NEUTRAL
2/10
Medifast (MED) issued a press release promoting the OPTAVIA coaching model, citing a 2019 randomized
May 21, 2026
NEUTRAL
2/10
Medifast (MED) issued a press release highlighting OPTAVIA's clinical research portfolio, including
May 15, 2026
NEUTRAL
2/10
Medifast issued a press release promoting OPTAVIA's clinical evidence for visceral fat reduction and
May 15, 2026
Historical analyst distribution (last covering-analyst action Feb 2026): 0% buy across 9 analysts — 0 strong buy, 0 buy, 4 hold, 4 sell, 1 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.00 mean target (Feb 2026)
$12.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $11.27 |
| Target Low | $12.00 |
| Target Mean | $12.00 |
| Target Median | $12.00 |
| Target High | $12.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.65 | $-0.65 | $-0.65 | -395.5% | -51.2% | 0↑ 1↓ | $0.1B | -31.1% | 1 |
| Next Q 2026-09-30 |
$-0.62 | $-0.62 | $-0.62 | -195.2% | -63.2% | 0↑ 1↓ | $0.1B | -24.3% | 1 |
| Current FY 2026-12-31 |
$-1.85 | $-1.85 | $-1.85 | -8.8% | +6.6% | 1↑ 0↓ | $0.3B | — | 1 |
| Next FY 2027-12-31 |
$-0.60 | $-0.60 | $-0.60 | 67.6% | +78.3% | 1↑ 0↓ | $0.3B | -8.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.650 | |
| 7d ago | $-0.430 | -0.220 |
| 30d ago | $-0.430 | -0.220 |
| 60d ago | $-0.430 | -0.220 |
| 90d ago | $-0.290 | -0.360 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 19, 2026 | Stephens & Co. | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| May 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Apr 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 4 | 1 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
other
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
OPTAVIA's clinical program reduces visceral fat 14% and retains 98% lean mass, directly addressing the metabolic impact of perimenopause and menopause
Jun 11, 2026
other
What Science-Backed Subscription Health Programs Measure Differently
OPTAVIA's RCT used DXA scanning and a 92.3% completion rate to document 98% lean mass retained in 198 participants across 16 weeks.
May 21, 2026
fda
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
OPTAVIA, backed by 18 RCTs, shows coach-guided weight loss delivers up to 10x more weight loss and 17x more fat loss than app-only programs.
May 21, 2026
fda
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
OPTAVIA's coach-guided model delivers up to 10x more weight loss and 17x more fat loss than self-directed weight management, per peer-reviewed RCT.
May 15, 2026
fda
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
Peer-reviewed research is redefining weight loss program standards, with OPTAVIA's RCT showing 98% lean mass preservation over 16 weeks.
May 15, 2026
fda
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
Peer-reviewed research shows OPTAVIA's structured meal replacement program reduces visceral fat 14% and preserves 98% lean mass over 16 weeks.
May 4, 2026
earnings_calendar
MED Q1 2026 Earnings Scheduled — 2026-05-04
Mar 23, 2026
short_interest
FTD: MED — 153,515 shares ($1.5M) failed to deliver
Settlement: 20260323, Price: $10.00, FTD Value: $1,535,150, MEDIFAST INC
Mar 13, 2026
short_interest
FTD: MED — 74,638 shares ($0.7M) failed to deliver
Settlement: 20260313, Price: $9.53, FTD Value: $711,300.14, MEDIFAST INC
Mar 12, 2026
short_interest
FTD: MED — 115,778 shares ($1.2M) failed to deliver
Settlement: 20260312, Price: $10.12, FTD Value: $1,171,673.36, MEDIFAST INC